Background And Aim: Colon carcinoma, as one of the most common cancers, has been investigated for genetic alterations. Besides well-known adenoma-carcinoma sequence, it is recently found that BRAF mutation had an important role particularly in early stages of adenocarcinomas with serrated features. There are no any studies concerning immunohistochemical expression status of BRAF V600E (VE1) antibody in serrated polyps in the Turkish population. The objective of this study is to observe the immunohistochemical staining of BRAF V600E (VE1) antibody in colon polyps in the Turkish population and investigate the frequency of presence of mutated BRAF proteins indicating malignant potential.
Materials And Methods: 59 cases of serrated polyps (27 cases of hyperplastic polyps, 18 cases of sessile serrated adenoma/polyps and 14 cases of traditional serrated adenomas) and 10 tubular adenomas, and 10 samples of normal colonic mucosa were immunohistochemically evaluated for the presence of BRAF V600E mutated proteins with the VE1 antibody. Results were statistically compared.
Results: All SSA/Ps; 92.8% of TSAs; 37% of HPs were stained positively. Of the 27 hyperplastic polyps, all GCHPs were negative but 10 of 12 MVHPs (83.3%) were weakly positive with the VE1 antibody. Cases in control groups and tubular adenomas didn't show any cytoplasmic staining.
Conclusion: Serrated adenoma/polyps have been gaining much more importance because of their malignant potential. Their frequency is also relatively high in the Turkish population and they should be carefully handled. Detection of BRAF V600E status can be easily achieved immunohistochemically by VE1 antibody. It is easily applicable and reproducible method and it might be helpful in identifying serrated lesions of the colon in addition to morphological features.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965429 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Expression of Mutated Kinase in Canine Carcinomas-An Immunohistochemical Study.
Vet Sci
November 2024
Institute of Animal Pathology, COMPATH, University of Bern, 3012 Bern, Switzerland.
Alterations of the gene and the resulting changes in the BRAF protein are one example of molecular cancer profiling in humans and dogs. We tested 227 samples of canine carcinomas from different anatomical sites (anal sac ( = 23), intestine ( = 21), liver ( = 21), lungs ( = 19), mammary gland ( = 20), nasal cavity ( = 21), oral epithelium ( = 18), ovary ( = 20), prostate ( = 21), thyroid gland ( = 21), urinary bladder ( = 22)) with two commercially available primary anti-BRAF antibodies (VE1 Ventana, VE1 Abcam). The immunohistochemical results were confirmed with droplet digital PCR (ddPCR).
View Article and Find Full Text PDFAnalysis of safety and efficacy of proton radiotherapy for optic nerve sheath meningioma.
Neurooncol Adv
September 2024
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Article Synopsis
- Primary optic nerve sheath meningiomas (ONSMs) are benign tumors that can cause gradual vision loss, and radiation therapy, particularly proton therapy, is key for treatment as it may improve visual function while minimizing side effects.* -
- In a study of 32 patients treated with proton beam radiotherapy, results showed a 100% local control rate after 5 years and 84.4% of patients experienced improved or stable vision, despite a 9.4% occurrence of radiation-induced optic neuropathy (RION).* -
- The findings support proton beam therapy as a safe and effective option for ONSM treatment, though further research is needed to compare its effectiveness against traditional photon radiotherapy.*
Article Synopsis
- Pediatric low-grade glioma (pLGG) is mainly caused by genomic changes in the MAPK pathway, particularly KIAA1549::BRAF fusions and BRAF V600E mutations, making it suitable for targeted therapies like tovorafenib instead of traditional treatments.
- The combination of dabrafenib and trametinib is FDA-approved for BRAF V600E-pLGG but not effective for tumors with BRAF fusions, as it may worsen tumor growth.
- The LOGGIC/FIREFLY-2 trial is assessing tovorafenib against standard chemotherapy in patients under 25 with pLGG and BRAF mutations, focusing on overall response rate and safety.
Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.
Neuro Oncol
April 2024
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Background: Novel radiotherapeutic modalities using carbon ions provide an increased relative biological effectiveness (RBE) compared to photons, delivering a higher biological dose while reducing radiation exposure for adjacent organs. This prospective phase 2 trial investigated bimodal radiotherapy using photons with carbon-ion (C12)-boost in patients with WHO grade 2 meningiomas following subtotal resection (Simpson grade 4 or 5).
Methods: A total of 33 patients were enrolled from July 2012 until July 2020.
V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients.
Medicina (Kaunas)
June 2023
School of Medicine, Pusan National University, Beomeori, Mulgeum-eop, Yangsan 50612, Republic of Korea.
mutational status in resected non-small cell lung cancer (NSCLC) in the Korean population is poorly understood. We explored (particularly V600E) mutational status among Korean patients with NSCLC. : This study included 378 patients with resected primary NSCLC who were enrolled from January 2015 to December 2017.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!